Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma

Hao Wei Teng; Man Hsin Hung; Li Ju Chen; Mao Ju Chang; Feng Shu Hsieh; Ming Hsien Tsai; Jui Wen Huang; Chih Lung Lin; Hsiang Wen Tseng; Zong Keng Kuo; Jeng Kai Jiang; Shung Haur Yang; Chung Wai Shiau; Kuen Feng Chen

doi:10.1038/srep35308

Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma

Hao Wei Teng, Man Hsin Hung, Li Ju Chen, Mao Ju Chang, Feng Shu Hsieh, Ming Hsien Tsai, Jui Wen Huang, Chih Lung Lin, Hsiang Wen Tseng, Zong Keng Kuo, Jeng Kai Jiang, Shung Haur Yang, Chung Wai Shiau, Kuen Feng Chen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Protein tyrosine phosphatase 1B (PTP1B) is known to promote the pathogenesis of diabetes and obesity by negatively regulating insulin and leptin pathways, but its role associated with colon carcinogenesis is still under debate. In this study, we demonstrated the oncogenic role of PTP1B in promoting colon carcinogenesis and predicting worse clinical outcomes in CRC patients. By co-immunoprecipitation, we showed that PITX1 was a novel substrate of PTP1B. Through direct dephosphorylation at Y160, Y175 and Y179, PTP1B destabilized PITX1, which resulted in downregulation of the PITX1/p120RasGAP axis. Interestingly, we found that regorafenib, the approved target agent for advanced CRC patients, exerted a novel property against PTP1B. By inhibiting PTP1B activity, regorafenib treatment augmented the stability of PITX1 protein and upregulated the expression of p120RasGAP in CRC. Importantly, we found that this PTP1B-dependant PITX1/p120RasGAP axis determines the in vitro anti-CRC effects of regorafenib. The above-mentioned effects of regorafenib were confirmed by the HT-29 xenograft tumor model. In conclusion, we demonstrated a novel oncogenic mechanism of PTP1B on affecting PITX1/p120RasGAP in CRC. Regorafenib inhibited CRC survival through reserving PTP1B-dependant PITX1/p120RasGAP downregulation. PTP1B may be a potential biomarker predicting regorafenib effectiveness, and a potential solution for CRC.

Original language	English
Article number	35308
Journal	Scientific reports
Volume	6
DOIs	https://doi.org/10.1038/srep35308
State	Published - 18 Oct 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/srep35308

Cite this

Teng, H. W., Hung, M. H., Chen, L. J., Chang, M. J., Hsieh, F. S., Tsai, M. H., Huang, J. W., Lin, C. L., Tseng, H. W., Kuo, Z. K., Jiang, J. K., Yang, S. H., Shiau, C. W., & Chen, K. F. (2016). Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma. Scientific reports, 6, [35308]. https://doi.org/10.1038/srep35308

@article{da761dc993e14359965da704550ca6b7,

title = "Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma",

abstract = "Protein tyrosine phosphatase 1B (PTP1B) is known to promote the pathogenesis of diabetes and obesity by negatively regulating insulin and leptin pathways, but its role associated with colon carcinogenesis is still under debate. In this study, we demonstrated the oncogenic role of PTP1B in promoting colon carcinogenesis and predicting worse clinical outcomes in CRC patients. By co-immunoprecipitation, we showed that PITX1 was a novel substrate of PTP1B. Through direct dephosphorylation at Y160, Y175 and Y179, PTP1B destabilized PITX1, which resulted in downregulation of the PITX1/p120RasGAP axis. Interestingly, we found that regorafenib, the approved target agent for advanced CRC patients, exerted a novel property against PTP1B. By inhibiting PTP1B activity, regorafenib treatment augmented the stability of PITX1 protein and upregulated the expression of p120RasGAP in CRC. Importantly, we found that this PTP1B-dependant PITX1/p120RasGAP axis determines the in vitro anti-CRC effects of regorafenib. The above-mentioned effects of regorafenib were confirmed by the HT-29 xenograft tumor model. In conclusion, we demonstrated a novel oncogenic mechanism of PTP1B on affecting PITX1/p120RasGAP in CRC. Regorafenib inhibited CRC survival through reserving PTP1B-dependant PITX1/p120RasGAP downregulation. PTP1B may be a potential biomarker predicting regorafenib effectiveness, and a potential solution for CRC.",

author = "Teng, {Hao Wei} and Hung, {Man Hsin} and Chen, {Li Ju} and Chang, {Mao Ju} and Hsieh, {Feng Shu} and Tsai, {Ming Hsien} and Huang, {Jui Wen} and Lin, {Chih Lung} and Tseng, {Hsiang Wen} and Kuo, {Zong Keng} and Jiang, {Jeng Kai} and Yang, {Shung Haur} and Shiau, {Chung Wai} and Chen, {Kuen Feng}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2016.",

year = "2016",

month = oct,

day = "18",

doi = "10.1038/srep35308",

language = "English",

volume = "6",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma

AU - Teng, Hao Wei

AU - Hung, Man Hsin

AU - Chen, Li Ju

AU - Chang, Mao Ju

AU - Hsieh, Feng Shu

AU - Tsai, Ming Hsien

AU - Huang, Jui Wen

AU - Lin, Chih Lung

AU - Tseng, Hsiang Wen

AU - Kuo, Zong Keng

AU - Jiang, Jeng Kai

AU - Yang, Shung Haur

AU - Shiau, Chung Wai

AU - Chen, Kuen Feng

PY - 2016/10/18

Y1 - 2016/10/18

N2 - Protein tyrosine phosphatase 1B (PTP1B) is known to promote the pathogenesis of diabetes and obesity by negatively regulating insulin and leptin pathways, but its role associated with colon carcinogenesis is still under debate. In this study, we demonstrated the oncogenic role of PTP1B in promoting colon carcinogenesis and predicting worse clinical outcomes in CRC patients. By co-immunoprecipitation, we showed that PITX1 was a novel substrate of PTP1B. Through direct dephosphorylation at Y160, Y175 and Y179, PTP1B destabilized PITX1, which resulted in downregulation of the PITX1/p120RasGAP axis. Interestingly, we found that regorafenib, the approved target agent for advanced CRC patients, exerted a novel property against PTP1B. By inhibiting PTP1B activity, regorafenib treatment augmented the stability of PITX1 protein and upregulated the expression of p120RasGAP in CRC. Importantly, we found that this PTP1B-dependant PITX1/p120RasGAP axis determines the in vitro anti-CRC effects of regorafenib. The above-mentioned effects of regorafenib were confirmed by the HT-29 xenograft tumor model. In conclusion, we demonstrated a novel oncogenic mechanism of PTP1B on affecting PITX1/p120RasGAP in CRC. Regorafenib inhibited CRC survival through reserving PTP1B-dependant PITX1/p120RasGAP downregulation. PTP1B may be a potential biomarker predicting regorafenib effectiveness, and a potential solution for CRC.

AB - Protein tyrosine phosphatase 1B (PTP1B) is known to promote the pathogenesis of diabetes and obesity by negatively regulating insulin and leptin pathways, but its role associated with colon carcinogenesis is still under debate. In this study, we demonstrated the oncogenic role of PTP1B in promoting colon carcinogenesis and predicting worse clinical outcomes in CRC patients. By co-immunoprecipitation, we showed that PITX1 was a novel substrate of PTP1B. Through direct dephosphorylation at Y160, Y175 and Y179, PTP1B destabilized PITX1, which resulted in downregulation of the PITX1/p120RasGAP axis. Interestingly, we found that regorafenib, the approved target agent for advanced CRC patients, exerted a novel property against PTP1B. By inhibiting PTP1B activity, regorafenib treatment augmented the stability of PITX1 protein and upregulated the expression of p120RasGAP in CRC. Importantly, we found that this PTP1B-dependant PITX1/p120RasGAP axis determines the in vitro anti-CRC effects of regorafenib. The above-mentioned effects of regorafenib were confirmed by the HT-29 xenograft tumor model. In conclusion, we demonstrated a novel oncogenic mechanism of PTP1B on affecting PITX1/p120RasGAP in CRC. Regorafenib inhibited CRC survival through reserving PTP1B-dependant PITX1/p120RasGAP downregulation. PTP1B may be a potential biomarker predicting regorafenib effectiveness, and a potential solution for CRC.

UR - http://www.scopus.com/inward/record.url?scp=84993966790&partnerID=8YFLogxK

U2 - 10.1038/srep35308

DO - 10.1038/srep35308

M3 - Article

C2 - 27752061

AN - SCOPUS:84993966790

SN - 2045-2322

VL - 6

JO - Scientific Reports

JF - Scientific Reports

M1 - 35308

ER -

Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this